HIV 感染



World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Sep 2015 [internet publication].全文

US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Jan 2022 [internet publication].全文

World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press; 2007 [internet publication].全文


1. Centers for Disease Control and Prevention. HIV infection: detection, counseling, and referral. In: Workowski KA, Bolan GA (eds). Sexually transmitted treatment guidelines, 2015. MMWR. 5 Jun 2015;(64):21-5.全文

2. World Health Organization. HIV/AIDS: online QA. Nov 2017 [internet publication].全文

3. Worobey M. The origins and diversifications of HIV. In: Volberding P, Sande M, Lange J, et al., eds. Global HIV/AIDS medicine. Philadelphia, PA: Elsevier; 2008.

4. Wilson D, Naidoo S, Bekker LG, et al. Handbook of HIV medicine. South Africa: Oxford University Press; 2002.

5. Robertson DL, Anderson JP, Bradac JL, et al. HIV-1 nomenclature proposal. Science. 2000 Apr 7;288(5463):55-6. 摘要

6. Hemelaar J, Elangovan R, Yun J, et al. Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis. Lancet Infect Dis. 2018 Nov 30. pii: S1473-3099(18)30647-9. 摘要

7. Yamaguchi J, McArthur C, Vallari A, et al. Complete genome sequence of CG-0018a-01 establishes HIV-1 subtype L. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):319-22. 摘要

8. Wymant C, Bezemer D, Blanquart F, et al. A highly virulent variant of HIV-1 circulating in the Netherlands. Science. 2022 Feb 4;375(6580):540-5.全文  摘要

9. Gottlieb GS, Raugi DN, Smith RA. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV. 2018 Jul;5(7):e390-9. 摘要

10. Fidler S, Fox J. Primary HIV infection: a medical and public health emergency requiring rapid specialist management. Clin Med (Lond). 2016 Apr;16(2):180-3.全文  摘要

11. Joint United Nations Programme on HIV/AIDS. UNAIDS data 2021. 2021 [internet publication].全文

12. GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019 Dec;6(12):e831-9.全文  摘要

13. Li Z, Purcell DW, Sansom SL, et al. Vital signs: HIV transmission along the continuum of care - United States, 2016. MMWR Morb Mortal Wkly Rep. 2019 Mar 22;68(11):267-72.全文  摘要

14. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2021 – 2020 data. Stockholm: ECDC; 2021.全文

15. Martin V, Shah A, Mackay N, et al. HIV testing, new HIV diagnoses, outcomes and quality of care for people accessing HIV services: 2021 report. The annual official statistics data release (data to end of December 2020). Dec 2021, UK Health Security Agency, London.全文

16. Centers for Disease Control and Prevention. Estimated annual number of HIV infections - United States, 1981-2019. MMWR Morb Mortal Wkly. 2021 Jun 4:70(22);801-6.全文

17. Dailey AF, Gant Z, Hu X, et al. Association between social vulnerability and rates of HIV diagnoses among black adults, by selected characteristics and region of residence - United States, 2018. MMWR Morb Mortal Wkly Rep 2022;71:167-70.全文  摘要

18. Nyamweya S, Hegedus A, Jaye A, et al. Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev Med Virol. 2013 Jul;23(4):221-40. 摘要

19. Pope M, Hause AT. Transmission, acute HIV-1 infection and the quest to prevent infection. Nat Med. 2003 Jul;9(7):847-52. 摘要

20. Gupta R, Hill A, Sawyer AW, et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008 Sep 1;47(5):712-22.全文  摘要

21. Morris L, Cilliers T. Viral structure, replication, tropism, pathogenesis and natural history. In: Abdool Karim SS, Abdool Karim Q, eds. HIV/AIDS in South Africa. Cambridge University Press; 2005:79-89.

22. Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Def Syndr Hum Retrovirol. 1995 Oct 1;10(2):175-6. 摘要

23. Varghese B, Maher JE, Peterman TA, et al. Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis. 2002 Jan;29(1):38-43. 摘要

24. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992 Mar 28;304(6830):809-13.全文  摘要

25. Bell DM. Occupational risk of human immunodeficiency virus infection in health care workers: an overview. Am J Med. 1997 May 19;102(5B):9-15. 摘要

26. Cooper ER, Charurat M, Mofenson L, et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94. 摘要

27. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS. 2016 Nov 13;30(17):2665-83.全文  摘要

28. Tepper NK, Curtis KM, Cox S, et al. Update to U.S. medical eligibility criteria for contraceptive use, 2016: updated recommendations for the use of contraception among women at high risk for HIV infection. MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):405-10.全文  摘要

29. World Health Organization. Contraceptive eligibility for women at high risk of HIV: guidance statement - recommendations on contraceptive methods used by women at high risk of HIV. 2019 [internet publication].全文

30. Looker KJ, Elmes JAR, Gottlieb SL, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infect Dis. 2017 Dec;17(12):1303-16.全文  摘要

31. Looker KJ, Welton NJ, Sabin KM, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect Dis. 2020 Feb;20(2):240-9.全文  摘要

32. Marfatia YS, Pandya I, Mehta K. Condoms: Past, present, and future. Indian J Sex Transm Dis AIDS. 2015 Jul-Dec;36(2):133-9.全文  摘要

33. Hanum N, Cambiano V, Sewell J, et al. Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study. Lancet Public Health. 2020 Sep;5(9):e501-11.全文  摘要

34. Riddell J 4th, Amico KR, Mayer KH. HIV preexposure prophylaxis: a review. JAMA. 2018 Mar 27;319(12):1261-8. 摘要

35. Delaugerre C, Rodriguez C, Capitant C, et al. Drug resistance among patients who acquired HIV infection in a preexposure prophylaxis trial. AIDS. 2018;32(16):2353-61. 摘要

36. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update: a clinical practice guideline. Dec 2021 [internet publication].全文

37. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Sep 2015 [internet publication].全文

38. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019 Jun 11;321(22):2203-13.全文  摘要

39. Cohen SE, Sachdev D, Lee SA, et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018 Nov 29 [Epub ahead of print]. 摘要

40. Tumarkin E, Siedner MJ, Bogoch II. The BMJ 10-minute consultation: HIV pre-exposure prophylaxis (PrEP). BMJ. 2019 Jan 17;364:k4681.

41. US Food and Drug Administration. FDA approves first injectable treatment for HIV pre-exposure prevention. Dec 2021 [internet publication].全文

42. Marshall BDL, Goedel WC, King MRF, et al. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. Lancet HIV. 2018 Sep;5(9):e498-505.全文  摘要

43. HIV Prevention Trials Network. Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men. May 2020 [internet publication].全文

44. HIV Prevention Trials Network. HPTN 084 study demonstrates superiority of CAB LA to oral FTC/TDF for the prevention of HIV. Nov 2020 [internet publication].全文

45. Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel. JAMA. 2020 Oct 27;324(16):1651-69.全文  摘要

46. Antoni G, Tremblay C, Delaugerre C, et al. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. Lancet HIV. 2020 Feb;7(2):e113-20. 摘要

47. Grulich AE, Guy R, Amin J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018 Nov;5(11):e629-37. 摘要

48. Grulich AE, Jin F, Bavinton BR, et al; Expanded PrEP Implementation in Communities New South Wales (EPIC-NSW) research group. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. Lancet HIV. 2021 Jun 30:S2352-3018(21)00074-6. 摘要

49. Holt M, Lea T, Mao L, et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17. Lancet HIV. 2018 Aug;5(8):e448-56. 摘要

50. Finlayson T, Cha S, Xia M, et al; National HIV Behavioral Surveillance Study Group. Changes in HIV preexposure prophylaxis awareness and use among men who have sex with men - 20 urban areas, 2014 and 2017. MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603.全文  摘要

51. Lattré T, Van Holder C. Revisiting the functional severity scale of the Boston carpal tunnel questionnaire, a comment concerning the use of digital communication technology. Muscle Nerve. 2021 Jun;63(6):E57-8.全文  摘要

52. Nel A, van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016 Dec 1;375(22):2133-43.全文  摘要

53. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010 Sep 3;329(5996):1168-74.全文  摘要

54. Anglemyer A, Rutherford GW, Horvath T, et al. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009153.全文  摘要

55. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.全文  摘要

56. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016 Jul 12;316(2):171-81.全文  摘要

57. Bavinton BR, Pinto AN, Phanuphak N, et al; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018 Aug;5(8):e438-47. 摘要

58. PARTNER Study Group. HIV transmission risk through condomless sex in gay couples with suppressive ART: the PARTNER2 Study extended results in gay men. 2018 [internet publication].全文

59. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019 Jun 15;393(10189):2428-38.全文  摘要

60. LeMessurier J, Traversy G, Varsaneux O, et al. Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review. CMAJ. 2018 Nov 19;190(46):E1350-60.全文  摘要

61. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Jan 2022 [internet publication].全文

62. Sharma SC, Raison N, Khan S, et al. Male circumcision for the prevention of human immunodeficiency virus (HIV) acquisition: a meta-analysis. BJU Int. 2018 Apr;121(4):515-26.全文  摘要

63. Yuan T, Fitzpatrick T, Ko NY, et al. Circumcision to prevent HIV and other sexually transmitted infections in men who have sex with men: a systematic review and meta-analysis of global data. Lancet Glob Health. 2019 Apr;7(4):e436-47.全文  摘要

64. Delany-Moretlwe S, Gray G, Kagee A, et al. AIDS prevention in South Africa. South Afr J HIV Med. 2006;23:13-7.

65. Rubens M, Ramamoorthy V, Saxena A, et al. HIV vaccine: recent advances, current roadblocks, and future directions. J Immunol Res. 2015;2015:560347.全文  摘要

66. Leal L, Lucero C, Gatell JM, et al. New challenges in therapeutic vaccines against HIV infection. Expert Rev Vaccines. 2017 Jun;16(6):587-600. 摘要

67. Baden LR, Stieh DJ, Sarnecki M, et al. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV. 2020 Oct;7(10):e688-98.全文  摘要

68. Centers for Disease Control and Prevention. Laboratory testing for the diagnosis of HIV infection: updated recommendations. Jun 2014 [internet publication].全文

69. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection: United States, 2014. MMWR Recomm Rep. 2014;63(RR-03):1-10.全文  摘要

70. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva, Switzerland: WHO Press; 2007 [internet publication].全文

71. UNAIDS, World Health Organization. UNAIDS/WHO policy statement on HIV testing. Jun 2004 [internet publication].全文

72. World Health Organization. HIV drug resistance report 2019. Jul 2019 [internet publication].全文

73. Shepher J, Quinn T. Laboratory testing for HIV infection. In: Volberding P, Sande M, Lange J, et al., eds. Global HIV/AIDS medicine. Philadelphia, PA: Elsevier; 2008:101-7.

74. Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009 Nov 15;49(10):1582-90.全文  摘要

75. Aves T, Tambe J, Siemieniuk RA, et al. Antiretroviral resistance testing in HIV-positive people. Cochrane Database Syst Rev. 2018 Nov 9;(11):CD006495.全文  摘要

76. Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: sexual assault and abuse and STDs. Jun 2015 [internet publication].全文

77. Ochodo EA, Olwanda EE, Deeks JJ, et al. Point‐of‐care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities. Cochrane Database Syst Rev. 2022 Mar 10;3(3):CD013208.全文  摘要

78. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Jul 2017 [internet publication].全文

79. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006 Sep 22;55(RR-14):1-17;quiz CE1-4.全文  摘要

80. DiNenno EA, Prejean J, Irwin K, et al. Recommendations for HIV screening of gay, bisexual, and other men who have sex with men - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Aug 11;66(31):830-2.全文  摘要

81. Pitasi MA, Oraka E, Clark H, et al. HIV testing among transgender women and men - 27 states and Guam, 2014-2015. MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):883-7.全文  摘要

82. Pitasi MA, Delaney KP, Oraka E, et al. Interval since last HIV test for men and women with recent risk for HIV infection - United States, 2006-2016. MMWR Morb Mortal Wkly Rep. 2018 Jun 22;67(24):677-81.全文  摘要

83. US Preventive Services Task Force, Owens DK, Davidson KW, et al. Screening for HIV infection: US Preventive Services Task Force recommendation statement. JAMA. 2019 Jun 18;321(23):2326-36.全文  摘要

84. The Voluntary HIV Counseling and Testing Efficacy Study Group. Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania and Trinidad: a randomised trial. Lancet. 2000 Jul 8;356(9224):103-12. 摘要

85. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Feb 2022 [internet publication].全文

86. Grobler L, Siegfried N, Visser ME, et al. Nutritional interventions for reducing morbidity and mortality in people with HIV. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD004536.全文  摘要

87. Olsen MF, Abdissa A, Kaestel P, et al. Effects of nutritional supplementation for HIV patients starting antiretroviral treatment: randomised controlled trial in Ethiopia. BMJ. 2014 May 15;348:g3187.全文  摘要

88. Visser ME, Durao S, Sinclair D, et al. Micronutrient supplementation in adults with HIV infection. Cochrane Database Syst Rev. 2017 May 18;(5):CD003650.全文  摘要

89. Teixeira NDSCCA, Pereira BM, Oliveira IKF, et al. Effect of vitamin D3 supplementation on HIV-infected adults: a systematic review. Nutr Hosp. 2019 Oct 17;36(5):1205-12.全文  摘要

90. Muzembo BA, Ngatu NR, Januka K, et al. Selenium supplementation in HIV-infected individuals: A systematic review of randomized controlled trials. Clin Nutr ESPEN. 2019 Dec;34:1-7.全文  摘要

91. US Department of Health and Human Services. HIV and immunizations. Aug 2021 [internet publication].全文

92. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015 Aug 27;373(9):795-807.全文  摘要

93. Mateo-Urdiales A, Johnson S, Smith R, et al. Rapid initiation of antiretroviral therapy for people living with HIV. Cochrane Database Syst Rev. 2019 Jun 17;(6):CD012962.全文  摘要

94. Feng Q, Zhou A, Zou H, et al. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019 Jul 8;366:l4179.全文  摘要

95. National Institute for Health Research. NIHR Signal: Four-drug treatment for HIV offers no benefit over standard three-drug treatment. Sep 2019 [internet publication].全文

96. Cahn P, Madero JS, Arribas J, et al. Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naive adults with HIV-1 infection - 48-week results from the GEMINI studies. Paper presented at: 22nd International AIDS Conference (AIDS 2018). 2018. Amsterdam, Netherlands.全文

97. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. Dec 2018 [internet publication].全文

98. Wang H, Lu X, Yang X, et al. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: meta-analysis. Medicine (Baltimore). 2016 Oct;95(41):e5146.全文  摘要

99. Tao X, Lu Y, Zhou Y, et al. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Int J Infect Dis. 2020 Apr;93:108-17.全文  摘要

100. World Health Organization. Guidelines on the public health response to pretreatment HIV drug resistance: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: second edition June 2016. Jul 2017 [internet publication].全文

101. Lennox JL, Landovitz RJ, Ribaudo HJ, et al; ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7;161(7):461-71.全文  摘要

102. Lederman MM, Calabrese L, Funderburg NT, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011 Oct 15;204(8):1217-26.全文  摘要

103. Lindegren ML, Kennedy CE, Bain-Brickley D, et al. Integration of HIV/AIDS services with maternal, neonatal and child health, nutrition, and family planning services. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD010119.全文  摘要

104. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012 Sep;13(8):453-68. 摘要

105. Segarra-Newnham M, Soffler SL. Osteoporosis and vitamin D deficiency in HIV-positive patients. J Pharm Technol. 2011;27:251-7.

106. National Institute for Health and Care Excellence. Cabotegravir with rilpivirine for treating HIV-1. Jan 2022 [internet publication].全文

107. Rizzardini G, Overton ET, Orkin C, et al. Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506.全文  摘要

108. Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020 Nov;7(11):e740-51.全文  摘要

109. Emu B, Fessel J, Schrader S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018 Aug 16;379(7):645-54.全文  摘要

110. Gilead Sciences. Study to evaluate the safety and efficacy of lenacapavir in combination with an optimized background regimen in heavily treatment experienced participants living with HIV-1 infection with multidrug resistance (CAPELLA). Feb 2021 [internet publication].全文

111. Li L, Tian JH, Yang K, et al. Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection. Cochrane Database Syst Rev. 2014 Jul 26;(7):CD008439.全文  摘要

112. Lalezari JP, Latiff GH, Brinson C, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV. 2015 Oct;2(10):e427-37. 摘要

113. Murgatroyd C, Pirrie L, Tran F, et al. Structure-activity relationships of the human immunodeficiency virus type 1 maturation inhibitor PF-46396. J Virol. 2016 Aug 26;90(18):8181-97.全文  摘要

114. US National Library of Medicine. Study to evaluate the safety of a gene and cell therapy product in participants with HIV that is well-controlled on antiretroviral therapy. Sep 2020 [internet publication].全文

115. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003 May 12;163(9):1009-21.全文  摘要

116. O'Connor J, Smith C, Lampe FC, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017 Jul;4(7):e295-302.全文  摘要

117. Nance RM, Delaney JAC, Simoni JM, et al. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study. Ann Intern Med. 2018;169(6):376-84.全文  摘要

118. Bosh KA, Johnson AS, Hernandez AL, et al. Vital signs: deaths among persons with diagnosed HIV infection, United States, 2010-2018. MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1717-24.全文  摘要

119. Teeraananchai S, Kerr SJ, Amin J, et al. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017 Apr;18(4):256-66. 摘要

120. Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017 Aug;4(8):e349-56.全文  摘要

121. Engels EA, Yanik EL, Wheeler W, et al. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clin Infect Dis. 2017 Aug 15;65(4):636-43.全文

122. Gupta RK, Peppa D, Hill AL, et al. Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV. 2020 May;7(5):e340-7.全文  摘要

123. World Health Organization. First case of HIV cure in a woman after stem cell transplantation reported at CROI-2022. 2022 Mar 24 [internet publication].全文

124. Mandalia S, Westrop SJ, Beck EJ, et al. Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV Cohort, 1988-2010. PLoS One. 2012;7(2):e29844.全文  摘要

125. Lawn SD, Wilkinson RJ, Lipman MC, et al. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Resp Crit Care Med. 2008 Apr 1;177(7):680-5. 摘要

126. Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation. 2018;138(11):1100-12.全文  摘要

127. Losina E, Hyle EP, Borre ED, et al. Projecting 10-yr, 20-yr and lifetime risks of cardiovascular disease in persons living with HIV in the US. Clin Infect Dis. 2017 Oct 15;65(8):1266-71. 摘要

128. Beckman JA, Duncan MS, Alcorn CW, et al. Association of human immunodeficiency virus infection and risk of peripheral artery disease. Circulation. 2018 Jul 17;138(3):255-65.全文  摘要

129. Ryom L, Lundgren JD, El-Sadr W, et al. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 2018 Jun;5(6):e291-300. 摘要

130. Osibogun O, Ogunmoroti O, Michos ED, et al. HIV/HCV coinfection and the risk of cardiovascular disease: a meta-analysis. J Viral Hepat. 2017 Nov;24(11):998-1004. 摘要

131. Rao SG, Galaviz KI, Gay HC, et al. Factors associated with excess myocardial infarction risk in HIV-infected adults: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):224-30.全文  摘要

132. Feinstein MJ, Hsue PY, Benjamin LA, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019 Jul 9;140(2):e98-124.全文  摘要

133. Howard JFB, Rokx C, Smit C, et al. Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study. Lancet HIV. 2019 Mar;6(3):e173-81. 摘要

134. Abraham AG, Althoff KN, Jing Y, et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015 Mar 15;60(6):941-9.全文  摘要

135. Hileman CO, Eckard AR, McComsey GA. Bone loss in HIV: a contemporary review. Curr Opin Endocrinol Diabetes Obes. 2015 Dec;22(6):446-51. 摘要

136. Goh SSL, Lai PSM, Tan ATB, et al. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporos Int. 2018 Mar;29(3):595-613.全文  摘要

137. Pramukti I, Lindayani L, Chen YC, et al. Bone fracture among people living with HIV: A systematic review and meta-regression of prevalence, incidence, and risk factors. PLoS One. 2020;15(6):e0233501.全文  摘要

138. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009 Jan 2;23(1):41-50.全文  摘要

139. Yanik EL, Napravnik S, Cole SR, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013 Sep;57(5):756-64.全文  摘要

140. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2551-9.全文  摘要

141. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015 Oct 6;163(7):507-18.全文  摘要

142. Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014 May 15;28(8):1181-91. 摘要

143. Hessol NA, Whittemore H, Vittinghoff E, et al. Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study. Lancet HIV. 2018 Nov;5(11):e647-55. 摘要

144. Park LS, Tate JP, Sigel K, et al. Association of viral suppression with lower AIDS-defining and non-AIDS-defining cancer incidence in HIV-infected veterans: a prospective cohort study. Ann Intern Med. 2018 Jul 17;169(2):87-96. 摘要

145. Klein MB, Althoff KN, Jing Y, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 2016;63:1160-7.全文  摘要

146. Chan P, Brew BJ. HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV/AIDS Rep. 2014 Sep;11(3):317-24. 摘要

147. Eshun-Wilson I, Siegfried N, Akena DH, et al. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst Rev. 2018 Jan 22;(1):CD008525.全文  摘要

148. Monroe AK, Glesby MJ, Brown TT, et al. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2015 Feb 1;60(3):453-62.全文  摘要

149. Nansseu JR, Bigna JJ, Kaze AD, et al. Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Epidemiology. 2018 May;29(3):431-41.全文  摘要

150. Nduka CU, Stranges S, Kimani PK, et al. Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis. Diabetes Metab Res Rev. 2017 Sep;33(6). 摘要

151. Bhatia R, Murphy AB, Raper JL, et al. Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems. AIDS. 2015 Jan 2;29(1):77-81.全文  摘要

152. Crothers K, Morris A. HIV infection and lung function decline: challenges, clinical implications, and new questions. AIDS. 2013 May 15;27(8):1345-7. 摘要

153. Ensink RJH, Kuper H. Is hearing impairment associated with HIV? A systematic review of data from low- and middle-income countries. Trop Med Int Health. 2017 Dec;22(12):1493-504. 摘要

154. Brooks JT, Kawwass JF, Smith DK, et al. Effects of antiretroviral therapy to prevent HIV transmission to women in couples attempting conception when the man has HIV infection - United States, 2017. MMWR Morb Mortal Wkly Rep. 2017 Aug 18;66(32):859-60.全文  摘要

155. Kawwass JF, Smith DK, Kissin DM, et al. Strategies for preventing HIV infection among HIV-uninfected women attempting conception with HIV-infected men - United States. MMWR Morb Mortal Wkly Rep. 2017 Jun 2;66(21):554-7.全文  摘要

156. National Institute for Health and Care Excellence. HIV testing: increasing uptake among people who may have undiagnosed HIV. Dec 2016 [internet publication].全文

157. Fowler MG, Newell ML. Breast-feeding and HIV-1 transmission in resource-limited settings. J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):230-9. 摘要